Journal Mobile Options
Table of Contents
Vol. 41, No. 6, 2008
Issue release date: October 2008
Section title: Original Paper
Psychopathology 2008;41:371–378
(DOI:10.1159/000155215)

Cannabis-Induced Psychotic-Like Experiences Are Predicted by High Schizotypy

Confirmation of Preliminary Results in a Large Cohort

Stirling J. · Barkus E.J. · Nabosi L. · Irshad S. · Roemer G. · Schreudergoidheijt B. · Lewis S.
aDepartment of Psychology and Speech Pathology, Manchester Metropolitan University, Manchester, and bInstitute of Psychiatry, Kings College, London, cNeuroscience and Psychiatry Unit, University of Manchester, Manchester, UK; dDepartment for Psychodiagnostics, Saxion HSIJ, Deventer, The Netherlands

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 7/10/2007
Accepted: 1/15/2008
Published online: 9/12/2008

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 2

ISSN: 0254-4962 (Print)
eISSN: 1423-033X (Online)

For additional information: http://www.karger.com/PSP

Abstract

Background: Cannabis use has been identified as a possible risk factor for developing schizophrenia. In a previous paper we reported preliminary evidence that cannabis use increases the likelihood of psychosis-like experiences in non-clinical respondents who scored highly on a measure of schizotypy. We now present findings from pooled data from 3 new follow-up studies comprising a sample of 477 respondents, of whom 332 reported using cannabis at least once. Sampling and Methods: As in our previous study, the psychological effects of cannabis were assessed with the Cannabis Experiences Questionnaire, from which 3 subscales can be derived; encompassing pleasurable experiences, psychosis-like experiences and after-effects. The respondents also completed the brief Schizotypal Personality Questionnaire. Results: Cannabis use was reported by 70% of the sample. Use per se was not significantly related to schizotypy. However, high scoring schizotypes were more likely to report both psychosis-like experiences and unpleasant after-effects associated with cannabis use. The pleasurable effects of cannabis use were not related to schizotypy. Exploratory factor analysis of the pooled data from this study and our previous report (providing a sample of >400 cannabis users) suggested a 3-factor solution. These were characterised as a psychotic-dysphoric index (factor 1), an expansive index (factor 2) and an intoxicated index (factor 3). Schizotypy was highly correlated with factors 1 and 3, though not with factor 2. Conclusion: High scoring schizotypes who use cannabis are more likely to experience psychotic-dysphoric phenomena and intoxicating effects during and after use. Our results confirm and expand the findings reported in our previous study. They are consistent with the hypothesis that cannabis use may be a risk factor for full psychosis in this group.


  

Author Contacts

John Stirling
Psychology and Speech Pathology, Manchester Metropolitan University
Elizabeth Gaskell Building, Hathersage Road
Manchester M13 0JA (UK)
Tel. +44 161 2472 561, Fax +44 161 2476 364, E-Mail j.stirling@mmu.ac.uk

  

Article Information

Received: July 10, 2007
Accepted after revision: January 15, 2008
Published online: September 12, 2008
Number of Print Pages : 8
Number of Figures : 0, Number of Tables : 2, Number of References : 37

  

Publication Details

Psychopathology (International Journal of Descriptive and Experimental Psychopathology, Phenomenology and Psychiatric Diagnosis)

Vol. 41, No. 6, Year 2008 (Cover Date: October 2008)

Journal Editor: Mundt C. (Heidelberg), Akiskal H.S. (San Diego, Calif.), Mezzich J.E. (New York, N.Y.)
ISSN: 0254–4962 (Print), eISSN: 1423–033X (Online)

For additional information: http://www.karger.com/PSP


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 7/10/2007
Accepted: 1/15/2008
Published online: 9/12/2008

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 2

ISSN: 0254-4962 (Print)
eISSN: 1423-033X (Online)

For additional information: http://www.karger.com/PSP


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.